

Information on Voting Rights and Denominator

Liège, Belgium – January 22, 2025, 06.00 PM CET – Regulated information - In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market, Hyloris Pharmaceuticals SA ('Hyloris') publishes the below information.

- Total Share capital: EUR 140,001.87
- Total number of securities carrying voting rights: 28,000,374 (all ordinary shares)
- Total number of voting rights (= denominator): 28,000,374 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
 - Pursuant to the ESOP Warrants plan 2020: 119,500 subscription rights cancelled and 61,000 remaining subscription rights giving right to 61,000 ordinary shares
 - Pursuant to the ESOP Warrants plan 2022: 95,000 subscription rights cancelled and 28,813 remaining subscription rights giving right to 28,813 ordinary shares
 - Pursuant to the ESOP Warrants plan 2025: 650,000 new subscription rights giving right to 650,000 ordinary shares
 - In total: 739,813 subscription rights giving right to 739,813 ordinary shares

Following the expiry of 306,125 warrants under the ESOP Warrants plan 2019 on December 31, 2024, Hyloris announces that the Board of Directors approved the issuance of 650,000 warrants on 20 January 2025. These new warrants, issued under the ESOP Warrant plan 2025 are intended for key employees, consultants, members of the management team and certain directors. These new warrants were issued on 20 January 2025 concomitantly with the cancellation of 214,500 existing warrants.

The warrants issued under the ESOP Warrant plan 2025 have a duration of six years as of the date of issuance. The warrants are subject to vesting conditions over a four-year period. They are generally not transferable and, in principle, cannot be exercised prior to the fourth anniversary of the grant date (i.e. 20 January 2029). Each warrant gives the right to subscribe to one new share of Hyloris. Should the warrants be exercised, Hyloris will apply for the listing of the resulting new shares on Euronext Brussels. The warrants as such will not be listed on any stock exchange market.



For more information, contact Hyloris:

Stijn Van Rompay, Co-CEO
Stijn.vanrompay@hyloris.com
+32 (0)4 346 02 07

Thomas Jacobsen, Co-CEO
Thomas.jacobsen@hyloris.com

About Hyloris Pharmaceuticals SA

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.

The Company's development strategy primarily focuses on leveraging existing regulatory pathways, such as the FDA's 505(b)2 pathway in the U.S or similar regulatory frameworks in other region which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This type of regulatory pathway can reduce the clinical burden required to bring a product to market, significantly shorten the development timelines and reduce costs and risks.

Hyloris has built a broad, patented portfolio of 19 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in early phases of commercialization with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. Outside its core strategic focus, the Company also has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development.

Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

